What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Breast cancer
Eric P. Winer mainly investigates Internal medicine, Breast cancer, Oncology, Cancer and Chemotherapy.
His Internal medicine research includes elements of Gynecology and Surgery.
His research integrates issues of Chemotherapy regimen, Radiation therapy and Adjuvant therapy in his study of Breast cancer.
His Oncology research incorporates elements of Clinical trial, Trastuzumab, Randomized controlled trial, Paclitaxel and Mastectomy.
His Cancer study combines topics from a wide range of disciplines, such as Germline mutation and Pathology.
His study looks at the relationship between Chemotherapy and fields such as Anthracycline, as well as how they intersect with chemical problems.
His most cited work include:
- Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 (1828 citations)
- American Society of Clinical Oncology Guideline Recommendations for Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer (1459 citations)
- Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741 (1248 citations)
What are the main themes of his work throughout his whole career to date?
Eric P. Winer mainly focuses on Internal medicine, Breast cancer, Oncology, Cancer and Metastatic breast cancer.
His studies examine the connections between Internal medicine and genetics, as well as such issues in Surgery, with regards to Cohort.
His study in Breast cancer is interdisciplinary in nature, drawing from both Stage, Gynecology and Disease.
His Oncology research integrates issues from Adjuvant therapy, Regimen, Paclitaxel and Phases of clinical research.
Eric P. Winer combines subjects such as Adverse effect, Family medicine and Pathology with his study of Cancer.
His Metastatic breast cancer research is multidisciplinary, relying on both Cancer research, Tolerability, Letrozole, Clinical endpoint and Fulvestrant.
He most often published in these fields:
- Internal medicine (70.91%)
- Breast cancer (71.02%)
- Oncology (61.70%)
What were the highlights of his more recent work (between 2017-2021)?
- Internal medicine (70.91%)
- Breast cancer (71.02%)
- Oncology (61.70%)
In recent papers he was focusing on the following fields of study:
His primary scientific interests are in Internal medicine, Breast cancer, Oncology, Metastatic breast cancer and Cancer.
His work carried out in the field of Breast cancer brings together such families of science as Stage, Adverse effect, Cancer research and Clinical trial.
The study incorporates disciplines such as Pembrolizumab, Hormone receptor, Trastuzumab and Chemotherapy in addition to Oncology.
His work deals with themes such as Regimen and Capecitabine, which intersect with Trastuzumab.
His Metastatic breast cancer course of study focuses on PARP inhibitor and Reversion and Germline.
His Cancer study incorporates themes from Bevacizumab, Epidemiology and Disease.
Between 2017 and 2021, his most popular works were:
- Breast Cancer Treatment: A Review. (580 citations)
- De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. (494 citations)
- Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials (293 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Breast cancer
Breast cancer, Internal medicine, Oncology, Metastatic breast cancer and Cancer are his primary areas of study.
The concepts of his Breast cancer study are interwoven with issues in Adverse effect, Capecitabine, Cohort and Immunotherapy.
Eric P. Winer works mostly in the field of Cohort, limiting it down to concerns involving Disease and, occasionally, Radiation therapy.
Eric P. Winer interconnects Clinical trial, Pertuzumab, Trastuzumab, Chemotherapy and Randomized controlled trial in the investigation of issues within Oncology.
The various areas that Eric P. Winer examines in his Metastatic breast cancer study include Exome sequencing, Cancer research, PARP inhibitor, Germline and Letrozole.
His Cancer study combines topics in areas such as Drug, Drug resistance and PTEN.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
